Endo is ramping up the next phase of its Dupuytren's contracture marketing drive. Not long after running its first branded ad for Xiaflex in the indication, the drugmaker has dubbed September the ...

– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the ...

The exact cause of Dupuytren’s contracture is unknown, but it is believed to have a strong genetic component. The condition is not caused by hand injuries or overuse, as some might think. Instead, it ...

An even less invasive treatment modality for Dupuytren contractures is CCH injections. The only FDA-approved injection in the U.S. is CCH, which is a preparation of two distinct collagenases that ...

MALVERN, Pa., March 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) for the treatment of ...

"Those with the best understanding of Dupuytren's contracture are patients who have faced similar challenges and uncertainties," said Justin Mattice, Vice President & General Manager, Branded ...

MALVERN, Pa., Feb. 17, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren's ...